Another study has assessed the survival rates of 670 breast cancer patients according to EGFR and HER2 expression levels and demonstrated that EGFR+ HER2+ patients have a worse disease-free survival and overall survival than EGFR- HER2-, EGFR+ HER2-, and EGFR- HER2+ patients [6]. This evidence concerns the gene ERBB2 and breast cancer.